Evidence Action: Comprehensive Company Profile

Background

Overview

Evidence Action is a global non-profit organization headquartered in Washington, D.C., dedicated to scaling low-cost, evidence-based health interventions to improve the well-being of millions in Africa and Asia. Founded in 2013, the organization focuses on addressing urgent health challenges through proven solutions, aiming to reach hundreds of millions of people living in poverty.

Mission and Vision

The mission of Evidence Action is to be a world leader in scaling evidence-based and cost-effective programs to reduce the burden of poverty. Its vision is to build a world where hundreds of millions of people in the poorest places have better opportunities and their lives are measurably improved.

Primary Area of Focus

The organization operates in seven countries across Africa and Asia, including India, Pakistan, Kenya, Uganda, Malawi, Nigeria, and Ethiopia. Its primary focus areas encompass maternal and newborn health, neglected tropical diseases, and child and adolescent health.

Industry Significance

Evidence Action is recognized for its data-driven approach to global health, emphasizing cost-effectiveness and scalability. Its programs have reached over 515 million people, demonstrating significant impact in the international development sector.

Key Strategic Focus

Core Objectives

Scaling Proven Interventions: Implementing and expanding health programs that have demonstrated effectiveness through rigorous evidence.

Cost-Effectiveness: Ensuring that interventions deliver maximum impact per dollar spent, optimizing resource utilization.

Global Reach: Extending the organization's programs to address health challenges in multiple countries, particularly in sub-Saharan Africa and South Asia.

Specific Areas of Specialization

Deworming Programs: Administering mass, school-based deworming treatments to children to improve health and educational outcomes.

Safe Water Access: Providing communities with access to safe drinking water through innovative chlorination technologies.

Maternal Health: Implementing syphilis screening programs for pregnant women to prevent congenital syphilis.

Key Technologies Utilized

Chlorination Systems: Deploying point-of-collection water chlorination systems to ensure safe drinking water.

Data Analytics: Utilizing rigorous research and data analysis to evaluate and scale health interventions.

Primary Markets or Conditions Targeted

Neglected Tropical Diseases: Addressing parasitic worm infections through deworming initiatives.

Waterborne Diseases: Preventing waterborne illnesses by providing access to safe water.

Maternal and Newborn Health: Reducing the incidence of congenital syphilis through screening programs.

Financials and Funding

Funding History

Evidence Action has received substantial support from various donors, including foundations, philanthropic organizations, and individual contributors. Notable supporters include the Gates Foundation, GiveWell, and MacKenzie Scott.

Total Funds Raised

As of 2022, the organization reported revenues exceeding $127 million, reflecting significant growth and donor confidence in its programs.

Recent Funding Rounds

In 2022, Evidence Action received substantial grants, including $48.8 million from Good Ventures for its Dispensers for Safe Water program and an additional $14 million for its Accelerator scheme.

Notable Investors

Good Ventures: Provided significant funding for the Dispensers for Safe Water program and the Accelerator scheme.

GiveWell: Committed over $64 million to the Dispensers for Safe Water program between 2017 and 2018.

MacKenzie Scott: Made a substantial donation to support the organization's initiatives.

Intended Utilization of Capital

The funds are primarily allocated to scaling existing programs, expanding into new regions, and developing innovative health interventions through the Accelerator program.

Pipeline Development

Key Pipeline Candidates

Deworm the World Initiative: A flagship program aiming to treat parasitic worm infections in children through mass, school-based deworming programs.

Safe Water Now: Providing communities with access to safe drinking water through point-of-collection chlorination systems.

Syphilis-Free Start: Implementing syphilis screening programs for pregnant women to prevent congenital syphilis.

Stages of Clinical Trials or Product Development

These programs are in various stages of implementation across multiple countries, with ongoing evaluations to assess effectiveness and scalability.

Target Conditions

Deworming Programs: Soil-transmitted helminth infections.

Safe Water Access: Waterborne diseases due to unsafe drinking water.

Maternal Health: Congenital syphilis in newborns.

Relevant Timelines for Anticipated Milestones

The organization continues to expand its programs, with ongoing assessments to refine and enhance intervention strategies.

Technological Platform and Innovation

Proprietary Technologies

Chlorination Systems: Innovative point-of-collection water chlorination technologies to ensure safe drinking water.

Significant Scientific Methods

Randomized Controlled Trials (RCTs): Utilized to evaluate the effectiveness of health interventions.

Data Analytics: Employing rigorous data analysis to inform program decisions and improvements.

Leadership Team

Key Executive Profiles

Kanika Bahl: Chief Executive Officer. Former Executive Vice President of the Clinton Health Access Initiative.

Danielle Bayer: Interim President.

Paul Byatta: Executive Vice President, Africa Region.

Ankur Garg: Executive Vice President and Country Director, India (EAII Advisors).

Jeff Grosz: Executive Vice President, Accelerator & Programs.

Anne Iden: Chief People Officer.

Anthony Latta: Chief Financial Officer.

Leadership Changes

In April 2026, Evidence Action announced Danielle Bayer as the next CEO, succeeding Kanika Bahl.

Competitor Profile

Market Insights and Dynamics

The global health non-profit sector is characterized by a growing emphasis on evidence-based interventions and cost-effectiveness. Organizations like Evidence Action are at the forefront of this movement, addressing critical health challenges in low-resource settings.

Competitor Analysis

The Deworm the World Initiative: Focuses on mass deworming programs for children.

Safe Water Network: Provides sustainable access to safe water in developing countries.

PATH: Develops and scales health innovations to improve global health.

Strategic Collaborations and Partnerships

Evidence Action collaborates with various governments, international organizations, and philanthropic entities to implement and scale its programs. Notable partnerships include those with the Gates Foundation, GiveWell, and MacKenzie Scott.

Operational Insights

The organization's focus on cost-effectiveness and scalability differentiates it from competitors, enabling it to reach a larger population with limited resources.

Strategic Opportunities and Future Directions

Evidence Action aims to double its impact by 2024, strengthening and expanding existing programs and identifying new evidence-based interventions to scale.